Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-05-14 Regulatory Filings
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Profound Medical has received FDA 510(k) clearance for a new AI module related to their medical device system. It describes the product, clinical validation studies, and includes forward-looking statements. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content is an update on a product approval and clinical validation, typical of a Capital/Financing Update or Regulatory Announcement. However, since it is primarily about FDA clearance and product development rather than financing or capital structure changes, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. The document length is over 10,000 characters and contains detailed information, not just a brief announcement or report publication notice.
2024-05-14 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-05-09 English
Interim MD&A - English.pdf
Regulatory Filings
2024-05-09 English
News release - English.pdf
Regulatory Filings
2024-05-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical evidence and scientific presentations related to Profound Medical's TULSA procedure. It discusses recent medical conference presentations and clinical trial data but does not contain financial statements, regulatory filings, or detailed financial performance data. It is not an earnings release, annual report, or any form of financial report. It is also not a regulatory filing, management change, or capital update. The content focuses on clinical and scientific updates rather than financial or governance information. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2024-05-06 English
Certificate re dissemination to shareholders.pdf
Regulatory Filings
2024-04-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.